With Trump and RFK challenging the stronghold of big pharma, the suppression of psychedelic medicines may soon be over. Analysts have set a price target of $26. Market conditions and fresh speculative details render these companies highly volatile and speculative, as many are in trial phases and are losing money rather than profiting... for now.